Application of medicinal pore fungus composition in sebum management and barrier repair of oily and sensitive skin

Abstract

The invention discloses the application of a medicinal pore fungus composition in oily and sensitive skin sebum management and barrier repair, and belongs to the technical field of cosmetics; the medicinal pore fungus composition provided by the invention includes the following components in parts by mass: 0.2-10 parts of a medicinal pore fungus extract, 0.2-10 parts of a red wine river extreme bacteria fermentation product, 0.1-5 parts of a mangrove kovoniella extract, 0.1-5 parts of a saffron extract, and 0.001-0.1 parts of epigallocatechin gallate glucoside. The medicinal pore fungus composition provided by the invention can endogenously promote the synthesis of long-chain fatty acids in the skin, reduce harmful short-chain fatty acids and saturated fatty acids, and inhibit lipid peroxidation, thereby optimizing the quality of sebum, achieving the effects of repairing, enhancing skin tolerance, and brightening the skin; and the medicinal pore fungus composition provided by the invention is friendly to oily and sensitive skin.

Description

Technical Field

[0001] The invention belongs to the technical field of cosmetics, and in particular relates to application of a medicinal pore fungus composition in sebum management and barrier repair of oily and sensitive skin. Background Art

[0002] Sebum plays an important protective role in the skin barrier. Reduced sebum quality will cause abnormal skin barrier function. Studies have shown that an increase in the content of short-chain fatty acids, a decrease in long-chain fatty acids, and an increase in the degree of fatty acid unsaturation will lead to loose skin structure, thereby affecting the skin barrier function. In addition, lipid peroxidation can lead to a dull complexion and induce skin inflammation.

[0003] Existing repair products that simply replenish sebum will burden oily and combination skin, leading to clogged pores, local inflammation, and ultimately exacerbating problems such as barrier damage and skin sensitivity. In addition, most of the added substances in existing commercial products that claim to optimize sebum quality are used to adjust the ratio of ceramide, cholesterol and triglycerides, without considering the length and unsaturation of lipid chains. Summary of the invention

[0004] The purpose of the present invention is to overcome the shortcomings of the above-mentioned prior art and provide a medicinal pore fungus composition that can effectively optimize sebum quality, repair, enhance skin tolerance and brighten skin tone, and at the same time will not burden oily sensitive skin for use in sebum management and barrier repair of oily sensitive skin.

[0005] To achieve the above-mentioned purpose, in a first aspect of the present invention, the present invention provides a medicinal pore fungus composition, which comprises the following components in parts by weight: 0.2-10 parts of a medicinal pore fungus extract, 0.2-10 parts of a fermentation product of red wine river extreme bacteria, 0.1-5 parts of a mangrove Kowarnia extract, 0.1-5 parts of a saffron extract, and 0.001-0.1 parts of epigallocatechin gallate glucoside.

[0006] The present invention selects a suitable proportion of medicinal phyllotoxin extract, red wine river extreme bacteria fermentation product, mangrove Covonella extract, saffron extract and epigallocatechin gallate glucoside, and the components work together to endogenously promote the synthesis of long-chain fatty acids in the skin, reduce harmful short-chain fatty acids and saturated fatty acids, and inhibit lipid peroxidation, thereby optimizing the quality of sebum and achieving the effects of repairing, enhancing skin tolerance, and brightening the skin; and the present invention is friendly to oily-sensitive skin through the optimization of components and their weight parts, does not bring a burden to oily-sensitive skin, and can achieve the improvement of the skin barrier repair ability of oily-sensitive skin.

[0007] Specifically, the medicinal pore mushroom extract is a natural product extracted from the medicinal mushroom pore mushroom. It is rich in polysaccharides, polyphenols, proteins and other ingredients, and has antioxidant, anti-inflammatory, antibacterial and other biological activities; the Red Wine River Extreme Bacteria is collected from the Rio Tinto River in Spain. It is a Bacillus that can withstand high temperatures, strong acids and strong radiation. Its fermentation products have the effects of DNA protection, barrier repair, red zone fading and moisturizing; the mangrove Kwoniella mangroviensis is a kind of bacteria collected from Quercus suber) bark, can produce the same or similar peptides, terpenes, flavonoids, polyphenols and alkaloids as the host, and its extract has skin rejuvenation activity, anti-inflammatory, anti-aging, anti-pollution and balance of flora; saffron extract is a natural product extracted from the petals of saffron, rich in flavonoids, especially glycosylated quercetin and kaempferol, and has strong anti-inflammatory, antibacterial and antioxidant activities; epigallocatechin gallate glucoside is one of the most effective active ingredients in tea polyphenols, has strong antioxidant activity, can scavenge free radicals, and reduce dull skin and inflammatory reactions caused by lipid peroxidation.

[0008] As a preferred embodiment of the medicinal pore fungus composition of the present invention, the medicinal pore fungus composition comprises the following components in parts by weight: 0.5-5 parts of medicinal pore fungus extract, 0.5-5 parts of red wine river extreme bacteria fermentation product, 0.5-3 parts of mangrove Kowarnia extract, 0.5-3 parts of saffron extract, and 0.01-0.05 parts of epigallocatechin gallate glucoside.

[0009] As a preferred embodiment of the medicinal pore fungus composition of the present invention, the medicinal pore fungus composition comprises the following components in parts by weight: 2-3 parts of medicinal pore fungus extract, 2-3 parts of red wine river extreme bacteria fermentation product, 1-2 parts of mangrove Kowarnia extract, 1-2 parts of saffron extract, and 0.02-0.03 parts of epigallocatechin gallate glucoside.

[0010] The present invention has found that the length of the fat chain is closely related to the skin barrier function. Short-chain fatty acids can cause the skin structure to be loose, while long-chain fatty acids can make the skin structure tight, thereby improving the skin barrier function and enhancing the skin barrier repair ability; and lipid peroxidation can cause unsaturated fatty acids to oxidize to form saturated fatty acids, resulting in a decrease in the unsaturation of fatty acids, thereby reducing the barrier repair ability of the skin; further, the present invention can improve the skin barrier function from the perspective of changing the proportion of long-chain fatty acids and changing the unsaturation of fatty acids by selecting suitable types of components and their mass fractions, increase the tightness of the skin structure and brighten the skin. At the same time, the present invention has found that the mass fraction of the components in the medicinal pore fungus composition will have a significant impact on the comprehensive performance of the product. When the mass fraction of the components in the medicinal pore fungus composition is further selected within the preferred range given by the present invention, the obtained product can better promote the synthesis of long-chain fatty acids, increase the chain length of fatty acids, and reduce lipid peroxidation, that is, the obtained product has a more obvious optimization effect on skin lipids, and the brightening effect on the skin and the effect of improving the skin barrier repair ability are more significant.

[0011] Preferably, in the medicinal pore fungus composition, the mass percentage of saffron extract is 0.4-50%.

[0012] More preferably, in the medicinal pore fungus composition, the mass percentage of saffron extract is 5-35%.

[0013] As a preferred embodiment of the medicinal pore fungus composition of the present invention, the preparation method of the medicinal pore fungus extract comprises the following steps: taking the medicinal pore fungus, crushing and sieving, adding water to extract, then filtering, collecting the filtrate for decolorization, separating the solid and liquid after decolorization, collecting the liquid and precipitating with alcohol, centrifuging after the alcohol precipitation and collecting the supernatant to obtain the medicinal pore fungus extract.

[0014] The present invention has found that the medicinal pore fungus extract is rich in polysaccharides, polyphenols, proteins and other components, and has excellent antioxidant, anti-inflammatory and antibacterial biological activities. The preparation method thereof will affect the effective components in the medicinal pore fungus extract and the synergistic effect with other components to a certain extent. When the extraction is further performed by decolorization and alcohol precipitation after water extraction, the obtained medicinal pore fungus extract is applied to the medicinal pore fungus composition of the present invention, and the comprehensive effect of the obtained medicinal pore fungus composition is more excellent.

[0015] As a preferred embodiment of the medicinal pore fungus composition of the present invention, the extraction temperature is 90-110° C., the extraction time is 1.5-2.5 hours, and the number of extractions is 2-3 times.

[0016] Preferably, the solid-liquid ratio in the leaching is 1 g: (15-25) mL.

[0017] As a preferred embodiment of the medicinal pore fungus composition of the present invention, the decolorization is performed by adding activated carbon to the filtrate and then heating and stirring.

[0018] Preferably, the amount of activated carbon added is 1.5% based on the mass of the filtrate.

[0019] Preferably, the decolorization temperature is 35-45°C.

[0020] As a preferred embodiment of the medicinal pore fungus composition of the present invention, the mass ratio of anhydrous ethanol to liquid in the collected liquid and precipitated with alcohol is (2-3):1.

[0021] As a preferred embodiment of the medicinal pore fungus composition of the present invention, the alcohol precipitation temperature is 5-10° C., and the alcohol precipitation time is 24-48 hours.

[0022] As a preferred embodiment of the medicinal pore fungus composition of the present invention, the mesh number of the sieve is 80-100 meshes.

[0023] As a preferred embodiment of the medicinal fusilli composition of the present invention, the medicinal fusilli further comprises a step of drying to a constant weight at 45-55° C. before being crushed.

[0024] As a preferred embodiment of the medicinal pore fungus composition of the present invention, the preparation method of the saffron extract comprises the following steps: taking saffron flowers, crushing and sieving them, adding them to an ethanol solution for ultrasonic extraction, and after the ultrasonic extraction is completed, centrifuging and collecting the supernatant and concentrating it to obtain the saffron extract.

[0025] The present invention has found that saffron extract is rich in flavonoids and has excellent anti-inflammatory, antibacterial and antioxidant activities. Especially when the saffron extract is prepared and extracted by the method provided by the present invention, the obtained saffron extract can better cooperate with other components to achieve a more excellent comprehensive effect.

[0026] As a preferred embodiment of the medicinal pore fungus composition of the present invention, the mass percentage of ethanol in the ethanol solution is 70-80%.

[0027] As a preferred embodiment of the medicinal pore fungus composition of the present invention, in the ultrasonic extraction, the temperature is 35-45°C, the time is 20-40 minutes, and the power is 70-90W.

[0028] As a preferred embodiment of the medicinal pore fungus composition of the present invention, the solid-liquid ratio in ultrasonic extraction is 1 g: (15-25) mL.

[0029] As a preferred embodiment of the medicinal pore fungus composition of the present invention, the mesh number of the sieve is 80-100 meshes.

[0030] As a preferred embodiment of the medicinal fusiformis composition of the present invention, the saffron flowers further include a step of drying at 45-55° C. to a constant weight before being crushed.

[0031] In the second aspect of the present invention, the present invention provides the use of the medicinal pore fungus composition in the preparation of cosmetics.

[0032] The present invention has found that the medicinal pore fungus composition provided by the present invention has excellent effects of increasing long-chain fatty acids and improving the unsaturation of fatty acids, thereby effectively improving sebum quality and skin barrier function, improving skin color, enhancing skin tolerance, and soothing sensitivity; therefore, it can be added as an effective component into the preparation of cosmetics to obtain the corresponding effects of the medicinal pore fungus composition. In addition, the medicinal pore fungus composition provided by the present invention will not burden oily sensitive skin while improving sebum quality, that is, it will not cause symptoms such as pore clogging and local verification after use, and can effectively enhance the skin barrier repair ability of oily sensitive skin and relieve sensitivity.

[0033] As a preferred embodiment of the application of the present invention, the cosmetics include any one of lotion, emulsion, cream, mask, essence, and spray.

[0034] In the third aspect of the present invention, the present invention provides a facial cream, which comprises the following components in mass percentage: 1-20% of a medicinal pore fungus composition, 0.05-0.3% of a thickener, 0.5-1% of a moisturizer, 0.5-5% of an emulsifier, 0.5-3% of a preservative, 0.01-0.3% of a pH regulator, and the remainder of water.

[0035] The present invention has found that when 1-20% of the medicinal pore fungus composition is added to the face cream, good comprehensive effects of the face cream can be achieved under the condition of appropriate addition amount.

[0036] As a preferred embodiment of the facial cream of the present invention, the thickener includes at least one of xanthan gum, carbomer, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, ammonium acryloyldimethyl taurate / VP copolymer, sclerotium gum, and cetyl alcohol.

[0037] As a preferred embodiment of the facial cream of the present invention, the moisturizer includes at least one of allantoin, sodium polyacrylate, hydrogenated lecithin, betaine, β-glucan, trehalose, caprylyl glycol, dipropylene glycol, sodium hyaluronate, 1,2-butylene glycol, glycerol, budding septin polysaccharide, and ceramide.

[0038] As a preferred embodiment of the facial cream of the present invention, the emulsifier includes at least one of caprylic / capric triglyceride, C14-22 alcohol, C12-20 alkyl glucoside, cetearyl glucoside, isononyl isononanoate, pentaerythritol tetrastearate, polydimethylsiloxane, stearyl alcohol, hydroxystearic acid, polymethylsilsesquioxane, pentaerythritol distearate, and sucrose stearate.

[0039] As a preferred embodiment of the facial cream of the present invention, the preservative includes at least one of 1,2-propylene glycol, 1,2-hexanediol, p-hydroxyacetophenone, and acrylates / C10-30 alkyl acrylate cross-linked polymer.

[0040] As a preferred embodiment of the facial cream of the present invention, the pH regulator includes at least one of arginine, tromethamine, and EDTA-disodium.

[0041] Compared with the prior art, the present invention has the following beneficial effects:

[0042] The present invention provides a kind of medicinal pore fungus composition for balancing sebum suitable for oily sensitive skin, by selecting medicinal pore fungus extract, red wine river extreme bacteria fermentation product, mangrove kovoniella extract, saffron extract and epigallocatechin gallate glucoside in appropriate mass parts, the components cooperate with each other, can promote the synthesis of long-chain fatty acids in the skin by endogenous, reduce harmful short-chain fatty acids and saturated fatty acids, inhibit lipid peroxidation, thereby realizing the optimization of sebum quality, achieving the effects of repairing, enhancing skin tolerance, brightening skin, and alleviating sensitivity; and, the present invention is friendly to oily sensitive skin through the optimization of components and their mass parts, and will not burden oily sensitive skin. The medicinal pore fungus composition provided by the present invention can be used in the preparation of cosmetics, and the prepared cosmetics are mild and non-irritating, and have good effects of repairing skin, brightening skin color, improving skin barrier repair ability and alleviating sensitivity. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 These are photos of the volunteers in Effect Example 3 before and after using the blank application example product;

[0044] Figure 2 These are photos of the volunteers in Effect Example 3 before and after using the product in Application Example 1. DETAILED DESCRIPTION

[0045] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0046] Unless otherwise specified, the reagents, methods and equipment used in the present invention are all conventional reagents, methods and equipment in the art; and unless otherwise specified, the raw materials used in parallel experiments are from the same batch of raw materials.

[0047] Red Wine River Extreme Bacteria Fermentation Product: MARSturizer TM , purchased from Lipotrue Company;

[0048] Mangrove Kowarnia Extract: Shiloxome TM , purchased from Provital;

[0049] Epigallocatechin Gallate Glucoside: EGCG, purchased from Givaudan;

[0050] Medicinal porphyra extract 1: Homemade, the preparation method includes the following steps:

[0051] The medicinal pore fungus was cleaned and placed in a 50°C constant temperature oven to dry to constant weight, ground and crushed, and passed through an 80-mesh sieve, the sieve was collected and 1 g of the material was added to 20 mL of distilled water, and extracted at 100°C for 2 hours, and repeated 3 times, and the extract was collected and filtered, and the filtrate was collected; activated carbon was added to the filtrate (the mass percentage of activated carbon was 1.5% based on the filtrate) and decolorized at 40°C; after the decolorization, the activated carbon was removed by centrifugation and filtration, and the filtrate was collected, and anhydrous ethanol was added to the filtrate (the mass ratio of anhydrous ethanol to filtrate was 2.5:1) and precipitated at 8°C for 48 hours, and then the supernatant was extracted by centrifugation to obtain the medicinal pore fungus extract 1;

[0052] Medicinal porphyra extract 2: Homemade, the preparation method includes the following steps:

[0053] The medicinal pore fungus was cleaned and placed in a 50°C constant temperature oven to dry to constant weight, ground and crushed, and passed through an 80-mesh sieve, the sieve was collected and 1 g of the material was added to 20 mL of 50% ethanol aqueous solution, and refluxed at 70°C for 2 hours, and repeated 3 times, and the extract was collected and filtered, and the filtrate was collected; activated carbon was added to the filtrate (the mass percentage of activated carbon was 1.5% based on the filtrate) and decolorized at 40°C; after the decolorization was completed, the activated carbon was removed by centrifugation and filtration, and the filtrate was collected, and anhydrous ethanol was added to the filtrate (the mass ratio of anhydrous ethanol to filtrate was 3:1) and precipitated at 8°C for 48 hours, and then the supernatant was extracted by centrifugation to obtain the medicinal pore fungus extract 2;

[0054] Saffron extract 1: Homemade, the preparation method includes the following steps:

[0055] Collect saffron flowers, clean them, put them into a 50°C constant temperature oven and dry them to constant weight, grind them and pass them through an 80-mesh sieve, collect the sieve-undersized material and take 1 g of it and add it into 20 mL of 75% ethanol aqueous solution, perform ultrasonic extraction at 40°C for 30 min, the ultrasonic extraction power is 80 W, then centrifuge, collect the supernatant and concentrate it under reduced pressure to 5 mL, to obtain saffron extract 1;

[0056] Saffron extract 2: Homemade, the preparation method includes the following steps:

[0057] Collect saffron flowers, clean them, put them into a 50°C constant temperature oven and dry them to constant weight, grind them and pass them through an 80-mesh sieve, collect the sieve-undersized material and take 1 g of it and add it into 20 mL of 75% ethanol aqueous solution, perform ultrasonic extraction at 60°C for 30 min, the ultrasonic extraction power is 80 W, then centrifuge, collect the supernatant and concentrate it under reduced pressure to 5 mL, to obtain saffron extract 2;

[0058] Saffron extract 3: Homemade, the preparation method includes the following steps:

[0059] Collect saffron flowers, clean them, put them into a 50°C constant temperature oven and dry them to constant weight, grind them and pass them through an 80-mesh sieve, collect the sieve-under material and take 1 g of it and add it to 20 mL of water, extract it at 100°C for 2 h, repeat 3 times, collect the extract and filter it, collect the filtrate and concentrate it under reduced pressure to 5 mL to obtain saffron extract 3.

[0060] Examples 1-8 and Comparative Examples 1-3

[0061] The embodiments and comparative examples of the present invention provide a medicinal fusilli composition, and the components (in parts by weight) of the medicinal fusilli composition are shown in Table 1;

[0062] Table 1

[0063]

[0064] The preparation method of the medicinal pore fungus composition provided in Example 1 is: mixing the components evenly to obtain the medicinal pore fungus composition.

[0065] The preparation methods of the medicinal pore fungus compositions in Examples 2-8 and Comparative Examples 1-3 are consistent with that in Example 1.

[0066] Comparative Example 4

[0067] The comparative example of the present invention provides a medicinal fusilli composition, and the only difference between the medicinal fusilli composition and Example 1 is that no medicinal fusilli extract is added.

[0068] Comparative Example 5

[0069] The comparative example of the present invention provides a medicinal pore fungus composition, and the only difference between the medicinal pore fungus composition and Example 1 is that the fermentation product of red wine river extreme bacteria is not added.

[0070] Comparative Example 6

[0071] The comparative example of the present invention provides a medicinal fusilli composition, and the only difference between the medicinal fusilli composition and Example 1 is that the mangrove Kewarnia extract is not added.

[0072] Comparative Example 7

[0073] The comparative example of the present invention provides a medicinal fusilli composition, and the only difference between the medicinal fusilli composition and Example 1 is that saffron extract is not added.

[0074] Comparative Example 8

[0075] The comparative example of the present invention provides a medicinal fusilli composition, and the only difference between the medicinal fusilli composition and Example 1 is that epigallocatechin gallate glucoside is not added.

[0076] Comparative Example 9

[0077] The comparative example of the present invention provides a medicinal phyllopore composition, wherein the medicinal phyllopore composition is different from Example 1 only in that the medicinal phyllopore extract is replaced by a PHELLINUS LINTEUS extract.

[0078] Comparative Example 10

[0079] The comparative example of the present invention provides a medicinal pore fungus composition, and the only difference between the medicinal pore fungus composition and Example 1 is that the fermentation product of Bacillus subtilis is used instead of the fermentation product of Extremophilus rubrum.

[0080] Comparative Example 11

[0081] The comparative example of the present invention provides a medicinal pore fungus composition, and the only difference between the medicinal pore fungus composition and Example 1 is that the extract of Saccharomyces cerevisiae is used instead of the extract of Covonella affine.

[0082] Comparative Example 12

[0083] The comparative example of the present invention provides a medicinal fusilli composition, and the only difference between the medicinal fusilli composition and Example 1 is that safflower extract is used instead of saffron extract.

[0084] Comparative Example 13

[0085] The comparative example of the present invention provides a medicinal fusilli composition, and the only difference between the medicinal fusilli composition and Example 1 is that catechol is used to replace epigallocatechin gallate glucoside.

[0086] Application examples 1-11, comparative application examples 1-13, blank application examples

[0087] The application examples, comparative application examples and blank examples of the present invention provide a facial cream, the components (mass percentage) of the facial cream are shown in Table 2; wherein the medicinal facies porcella compositions used in application examples 1-8 are respectively the medicinal facies porcella compositions prepared in embodiments 1-8, and the medicinal facies porcella compositions used in comparative application examples 1-13 are respectively the medicinal facies porcella compositions prepared in comparative examples 1-13; the medicinal facies porcella compositions used in application examples 9-11 are the medicinal facies porcella compositions prepared in embodiment 1;

[0088] Table 2

[0089]

[0090]

[0091] The preparation method of the facial cream provided in Application Example 1 comprises the following steps:

[0092] (1) Mix the humectant and thickener with water, heat to 85±2° C., homogenize at 1200 rpm for 4 min, and keep warm for later use to obtain prefabricated component A;

[0093] (2) Mix the emulsifier, heat to 85±2° C., homogenize at 1200 rpm for 4 min, and keep warm for later use to obtain prefabricated component B;

[0094] (3) Mix the preservatives and heat to 60±2°C to melt to obtain a prefabricated C component;

[0095] (4) The preformed component A is heated to 80±2°C, and the preformed component B is added at a speed of 250 rpm, and stirred and mixed. Then, the temperature is lowered to 60±2°C, and the preformed component C is added at a speed of 250 rpm and stirred and mixed. Then, the temperature is lowered to 40°C, and the medicinal pore fungus composition is added and stirred for 8 minutes. Finally, the remaining pH adjuster is added to adjust the pH to 6.0, and the stirring can be stopped. The material is discharged to obtain a facial cream.

[0096] The preparation methods of the facial creams provided in Application Examples 2-11, Comparative Application Examples 1-13 and Blank Application Examples are consistent with that in Application Example 1.

[0097] Effect Example 1

[0098] The effect examples of the present invention explore the effect of the medicinal pore fungus composition prepared by Examples 1-8 and Comparative Examples 1-13 on the synthesis of long-chain fatty acids. Since very long-chain fatty acid elongase is an important rate-limiting enzyme in the long-chain fatty acid synthesis pathway, this effect example detects the expression level of the very long-chain fatty acid elongase gene ELOVL1 of the cell to evaluate the promoting effect of the medicinal pore fungus composition on the synthesis of long-chain fatty acids.

[0099] The cell line used in this effect test is human keratinocyte HaCaT (Guangzhou Jinio Biotechnology Co., Ltd.), and the test conditions are: incubator temperature 37±1°C, humidity 90±5%, carbon dioxide 5±1%; cell culture and treatment are performed according to the grouping, and then the test is performed. The specific test is the ELOVL1 gene expression detection, and the test method is as follows:

[0100] (1) The cell suspension was inoculated into a 96-well cell culture plate at a density of 2000 cells per well, 100 μL of culture medium was added to each well, and cultured for 24 h;

[0101] (2) The supernatant was discarded, and 100 μL of DMEM medium (2105341, Gibco) was added to the blank control group, and 100 μL of medium containing 1% of the corresponding sample was added to the Example 1-8 group and the Comparative Example 1-13 group respectively;

[0102] (3) After incubation for 48 h, the supernatant was discarded, and the RNA of the cells was extracted using an RNA extraction kit (TRIzol, Thermo Fisher), and the RNA was reverse transcribed into cDNA using a reverse transcription kit (RevertAid RT, Thermo Fisher), and the synthesized cDNA was used as a template for real-time fluorescence quantitative PCR reaction (TaqMan, Thermo Fisher);

[0103] (4) Real-time fluorescence quantitative PCR was used to detect the ELOVL1 gene expression level of HaCaT cells in each group, using GAPDH as the internal reference gene, and the ELOVL1 primer sequence used was:

[0104] 5'-AACTCTTCCGTGCATGTCATAAT-3',

[0105] 5'-TGCTTTTTCCACCAAAGGTAGG-3';

[0106] The GAPDH primer sequences used were:

[0107] 5'-ACTTTGTCAAGCTCATTTCC-3',

[0108] 5′-TGCAGCGAACTTTATTGATG-3′;

[0109] (5) Calculate the ELOVL1 improvement rate: ELOVL1 improvement rate = ELOVL1 expression 样品处理 / ELOVL1 expression 空白对照 ×100%;

[0110] The results obtained are shown in Table 3;

[0111] Table 3

[0112] ELOVL1 improvement rate / % ELOVL1 improvement rate / % Example 1 178 Comparative Example 1 33 Example 2 143 Comparative Example 2 35 Example 3 128 Comparative Example 3 26 Example 4 84 Comparative Example 4 8 Example 5 95 Comparative Example 5 -4 Example 6 134 Comparative Example 6 -5 Example 7 142 Comparative Example 7 16 Example 8 140 Comparative Example 8 12 Comparative Example 9 16 Comparative Example 10 -8 Comparative Example 11 -8 Comparative Example 12 4 Comparative Example 13 6

[0113] It can be seen from Table 3 that when the technical solution provided by the present invention is adopted, the obtained medicinal pore fungus composition has an excellent effect of promoting the synthesis of long-chain fatty acids. Specifically, the ELOVL1 improvement rate is above 84%;

[0114] It can be seen from Examples 1-5 and Comparative Examples 1-3 that the mass fraction of the components in the medicinal pore fungus composition will affect the performance of the product. When the mass fraction of the components in Comparative Examples 1-3 is not within the range given in the present invention, the effect of the obtained product in promoting the synthesis of long-chain fatty acids is significantly reduced, and the ELOVL1 improvement rate is below 35%;

[0115] It can be seen from Example 1 and Comparative Examples 4-8 that the components are indispensable. When any one of the components is missing, the obtained product has a significantly reduced effect on promoting the production of long-chain fatty acids. It can be seen from Example 1 and Comparative Examples 9-13 that when other components are used to replace the components in the present invention, the corresponding effects cannot be achieved, and the ELOVL1 improvement rate is below 16%.

[0116] Effect Example 2

[0117] The effect example of the present invention explores the irritation of the cream prepared by application examples 1-11, comparative application examples 1-13 and blank application examples, specifically using a human patch test, including the following steps:

[0118] 30 volunteers were recruited, including 15 males and 15 females, aged 20-50 years old. The closed patch test method was used. An equal amount (0.020 mL-0.025 mL) of the test sample (Application Examples 1-11, Comparative Application Examples 1-13 and Blank Application Examples) was placed in a specific patch tester, which was applied to the volunteer's arm with a low-allergenic tape, and gently pressed to evenly apply it on the skin for 24 hours; the blank control group was distilled water; after 24 hours, the patch tester was removed, and the skin reaction was observed after 0.5 hours, 24 hours, and 48 hours, and the results were recorded; the level of adverse reactions to the skin is shown in Table 4 below;

[0119] Table 4

[0120]

[0121] The patch test results showed that the creams prepared in Application Examples 1-11, Comparative Application Examples 1-13 and Blank Application Examples all showed negative reactions, that is, they were safe and non-irritating to human skin.

[0122] Effect Example 3

[0123] The effect examples of the present invention explore the effect of the cream prepared by application examples 1-11, comparative application examples 1-13 and blank application examples on optimizing the quality of human sebum, as well as the repair and brightening effects on human skin; specifically, the following processes are included:

[0124] 130 Asian adult test subjects aged 18-60 with oily and sensitive skin were selected and randomly divided into 26 groups, with 5 people in each group. The volunteers used samples (creams prepared in Application Examples 1-11, Comparative Application Examples 1-13 and Blank Application Examples, and commercially available creams) on their entire faces once in the morning and evening every day, and data were collected on the 0th and 28th days of use;

[0125] After the visit, the volunteers washed their faces with facial cleanser and sat in an air-conditioned room at a temperature of 21±1℃ and a humidity of 50±10% for 2 hours. The researchers used skin tape D-SquameTM D100 to collect sebum from the volunteers' foreheads 5 times. After collecting the samples, lipidome sequencing analysis was performed (Wuhan Maiwei Metabolic Biotechnology Co., Ltd.). According to the sequencing results, the total chain length of fatty acids and the degree of unsaturation of fatty acids in the volunteers' skin were counted, and the improvement rate of the total chain length of fatty acids and the improvement rate of fatty acid unsaturation were calculated.

[0126] Among them, the total chain length improvement rate of fatty acids = [(T28 脂肪酸总链长 -T0 脂肪酸总链长 ) / T0 脂肪酸总链长 *100%]-[(T28 空白应用例脂肪酸总链长 -T0 空白应用例脂肪酸总链长 ) / T0 空白应用例脂肪酸总链长 *100%];

[0127] Fatty acid unsaturation improvement rate = [(T28 脂肪酸不饱和度 -T0 脂肪酸不饱和度 ) / T0 脂肪酸不饱和度 *100%]-[(T28 空白应用例脂肪酸不饱和度 -T0 空白应用例脂肪酸不饱和度 ) / T0 空白应用例脂肪酸不饱和度 *100%];

[0128] At the same time, use the skin moisture loss test probe ( TM Hex) was used to measure the transepidermal water loss value TEWL of the zygomatic bone, and the CK skin gloss test probe GL200 was used to determine the brightness L value of the zygomatic bone;

[0129] The skin barrier repair ability is expressed by the improvement of TEWL value, and the skin brightness is expressed by the improvement of L value. The formula is as follows:

[0130] TEWL improvement rate = [(T28 TEWL值 -T0 TEWL值 ) / T0 TEWL值 *100%]-[(T28 空白应用例TEWL

[0131] 值 -T0 空白应用例TEWL值 ) / T0 空白应用例TEWL值 *100%];

[0132] L value improvement rate = [(T28 L值 -T0 L值 ) / T0 L值 *100%]-[(T28 空白应用例L值 -T0 空白应用例L值 )

[0133] / T0 空白应用例L值 *100%];

[0134] The results obtained are shown in Table 5;

[0135] Table 5

[0136]

[0137]

[0138] It can be seen from Table 5 that when the technical solution provided by the present invention is adopted, the obtained facial cream has excellent effects of increasing the total chain length of fatty acids and increasing the unsaturation of fatty acids. At the same time, it can also effectively improve the skin barrier repair ability and brighten the skin; specifically, the improvement rate of the total chain length of fatty acids is more than 20%, the improvement rate of the unsaturation of fatty acids is more than 57%, the improvement rate of the TEWL value is more than 14.7%, and the improvement rate of the L value is more than 8.7%; wherein, during the test process, a random volunteer in the blank application example group was photographed before and after using the blank application example product as shown in the figure below. Figure 1 As shown, a random volunteer in the application example 1 group took photos before and after using the product of application example 1. Figure 2 shown; from Figure 1-2 It can be clearly seen that the product of Application Example 1 obtained by the preparation method of the present invention brightens the skin tone visibly;

[0139] It can be seen from Application Examples 1-5 and Comparative Application Examples 1-3 that the mass fraction of the components in the medicinal pore fungus composition will affect the performance of the product. When the mass fraction of the components in Comparative Application Examples 1-3 is not within the range given in the present invention, the optimization effect of the obtained cream on sebum quality is significantly reduced, the improvement rate of the total chain length of fatty acids is less than 7%, the improvement rate of fatty acid unsaturation is less than 21%, the improvement rate of TEWL value is less than 2.2%, and the improvement rate of L value is less than 3.9%; It can be seen from Application Examples 1 and Application Examples 9-11 that the added mass percentage of the medicinal pore fungus composition in the cream will also affect the comprehensive effect of the product. With the increase of the mass percentage of the medicinal pore fungus composition, the improvement effect of the cream on sebum quality, skin barrier repair ability and skin brightness first shows a significant increase trend and then slows down to almost unchanged;

[0140] It can be seen from Application Example 1 and Comparative Application Examples 4-8 that the components in the added medicinal pore fungus composition are indispensable. When any one of the components in the medicinal pore fungus composition is missing, the effect of the obtained cream on improving sebum quality is significantly reduced, and the ability to repair the skin barrier and brighten the skin tone shows a significant downward trend; It can be seen from Application Example 1 and Comparative Application Examples 9-13 that when other components in the medicinal pore fungus composition are used to replace the components in the medicinal pore fungus composition of the present invention, the corresponding effect cannot be achieved, and the improvement rate of the total chain length of fatty acids is less than 3%, the improvement rate of fatty acid unsaturation is less than 7%, the improvement rate of TEWL value is less than 0.8%, and the improvement rate of L value is less than 1.1%.

[0141] Effect Example 4

[0142] The effect example of the present invention explores the improvement effect of the cream prepared by application examples 1-11, comparative application examples 1-13 and blank application examples on human skin tolerance and sensitivity soothing ability, comprising the following steps:

[0143] According to the "Technical Specifications for Safety of Cosmetics" (2015), 130 Asian adult testers aged 18-60 with oily and sensitive skin were selected and randomly divided into 26 groups, with 5 people in each group. The volunteers used samples (creams prepared by Application Examples 1-11, Comparative Application Examples 1-13 and Blank Application Examples, and commercially available creams) on their entire faces once in the morning and evening every day, and visited to collect data on the 0th and 28th days of use. After the visit, the volunteers washed their faces with facial cleansers, sat in an air-conditioned room with a temperature of 21±1℃ and a humidity of 50±10% for 5 minutes, and then applied filter paper (about 0.8cm in diameter) soaked with 50μL 10% lactic acid aqueous solution to the nasolabial grooves on both sides of the subjects at the same time. At 2.5min and 5min, the subjects subjectively evaluated the burning sensation at the nasolabial grooves on both sides, and scored according to the 4-point method, with the scoring criteria being: 0 for no tingling, 1 for mild tingling, 2 for moderate tingling, and 3 for severe tingling. The two scores were added together, and the total score was ≥3 points, which was considered a positive lactic acid stinging reaction. The lower the score, the better the skin tolerance, and the higher the score, the worse the skin tolerance. The improvement rate of the lactic acid stinging score was calculated;

[0144] Among them, lactic acid stinging score improvement rate = [(T0 评分 -T28 评分 ) / T0 评分 *100%]-[(T0 空白应用例评分 -T28 空白应用例评分 ) / T0 空白应用例评分 *100%];

[0145] The results obtained are shown in Table 6;

[0146] Table 6

[0147] Lactic acid stinging score improvement rate / % Lactic acid stinging score improvement rate / % Commercially available facial cream 25 Comparative application example 1 21 Application Example 1 67 Comparative Application Example 2 24 Application Example 2 50 Comparative Application Example 3 23 Application Example 3 52 Comparative Application Example 4 12 Application Example 4 36 Comparative Application Example 5 9 Application Example 5 33 Comparative Application Example 6 11 Application Example 6 46 Comparative Application Example 7 3 Application Example 7 44 Comparative Application Example 8 7 Application Example 8 41 Comparative Application Example 9 8 Application Example 9 34 Comparative Application Example 10 10 Application Example 10 63 Comparative Application Example 11 8 Application Example 11 71 Comparative Application Example 12 4 Comparative Application Example 13 8

[0148] It can be seen from Table 6 that when the technical solution provided by the present invention is adopted, the obtained facial cream can significantly improve the lactic acid stinging phenomenon, that is, the facial cream provided by the present invention has excellent effects of improving skin tolerance and relieving sensitivity.

[0149] Finally, it should be noted that the above embodiments are intended to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention may be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A medicinal pore fungus composition, characterized in that: The medicinal pore fungus composition consists of the following components in parts by weight: 0.5-5 parts of medicinal pore fungus extract, 0.5-5 parts of red wine river extreme bacteria fermentation product, 0.5-3 parts of mangrove Kowarnia extract, 0.5-3 parts of saffron extract, and 0.01-0.05 parts of epigallocatechin gallate glucoside.

2. The medicinal pore fungus composition according to claim 1, characterized in that: The medicinal pore fungus composition is composed of the following components in parts by weight: 2-3 parts of medicinal pore fungus extract, 2-3 parts of red wine river extreme bacteria fermentation products, 1-2 parts of mangrove kovoniella extract, 1-2 parts of saffron extract, and 0.02-0.03 parts of epigallocatechin gallate glucoside.

3. The medicinal pore fungus composition according to claim 1, characterized in that The preparation method of the medicinal porphyra extract comprises the following steps: taking the medicinal porphyra, crushing and screening, then adding water for extraction, filtering, collecting the filtrate for decolorization, separating the solid and liquid after decolorization, collecting the liquid and performing alcohol precipitation, centrifuging after the alcohol precipitation and collecting the supernatant to obtain the medicinal porphyra extract.

4. The medicinal pore fungus composition according to claim 3, characterized in that: The leaching temperature is 90-110° C., the leaching time is 1.5-2.5 hours, and the leaching times are 2-3 times.

5. The medicinal pore fungus composition according to claim 1, characterized in that: The preparation method of the saffron extract comprises the following steps: taking saffron flowers, crushing and sieving them, adding them into an ethanol solution for ultrasonic extraction, and after the ultrasonic extraction is completed, centrifuging and collecting the supernatant and concentrating it to obtain the saffron extract.

6. The medicinal pore fungus composition according to claim 5, characterized in that: In the ethanol solution, the mass percentage of ethanol is 70-80%; And / or, during the ultrasonic extraction, the temperature is 35-45°C, the time is 20-40 min, and the power is 70-90W.

7. Use of the medicinal pore fungus composition according to any one of claims 1 to 6 in the preparation of cosmetics.

8. A facial cream, characterized in that: The facial cream is composed of the following components in percentage by mass: 1-20% of the medicinal pore fungus composition according to any one of claims 1 to 6, 0.05-0.3% of a thickener, 0.5-1% of a moisturizer, 0.5-5% of an emulsifier, 0.5-3% of a preservative, 0.01-0.3% of a pH regulator, and the balance of water.

9. The facial cream according to claim 8, characterized in that At least one of the following is met: a. The thickener comprises at least one of xanthan gum, carbomer, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, ammonium acryloyldimethyl taurate / VP copolymer, sclerotium gum, and cetyl alcohol; b. The moisturizing agent includes at least one of allantoin, sodium polyacrylate, hydrogenated lecithin, betaine, β-glucan, trehalose, caprylyl glycol, dipropylene glycol, sodium hyaluronate, 1,2-butylene glycol, glycerol, budding pullulan polysaccharide, and ceramide; c. The emulsifier includes at least one of caprylic / capric triglyceride, C14-22 alcohol, C12-20 alkyl glucoside, cetearyl glucoside, isononyl isononanoate, pentaerythritol tetrastearate, polydimethylsiloxane, stearyl alcohol, hydroxystearic acid, polymethylsilsesquioxane, pentaerythritol distearate, and sucrose stearate; d. The preservative includes at least one of 1,2-propylene glycol, 1,2-hexanediol, p-hydroxyacetophenone, and acrylates / C10-30 alkyl acrylate cross-polymer; e. The pH adjusting agent includes at least one of arginine, tromethamine, and EDTA-disodium.

Images